Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Efpeglenatide Has Cardiovascular and Renal Benefit Outcomes in Type 2 Diabetes
Risk of Herpes Zoster in Patients with Diabetes
The Diverse Patterns of HbA1c from Childhood to Adolescence
The Short-term Effects of Intermittent Fasting on Fat Metabolism
Targeting Lower A1C Levels May Reduce Mortality in the Elderly
Letter from the Editor
Our patients use Dr. Google all the time to self-diagnose and self-treat themselves. They also look for influencers on sites such as YouTube, TikTok, and Facebook. If you look at YouTube searches, the biggest visits are to weight loss videos, with a focus on keto and intermittent fasting. One caveat that appears in videos for either of these programs is decreased insulin secretion and how that causes you to burn fat. This week, our intern Destiny Reed, PharmD. Candidate, Florida A&M College of Pharmacy, takes a look at a peer-reviewed published medical study that compared Keto, IF and the Mediterranean diet, and how they affected insulin secretion, weight loss and A1c.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief
TOP STORIES — Diabetes News and Research
Efpeglenatide has proven to significantly reduce several risk factors for cardiovascular and kidney disease.
According to current research, linagliptin had a significantly lower risk of hypoglycemia and adverse events in geriatric patients with type 2 diabetes.
A systematic review found patients with diabetes were associated with a 38% increased risk of developing herpes zoster.
Identifying high-risk patients with unstable HbA1c levels from childhood to adolescence can have significant outcomes.
Intermittent fasting was shown to increase early morning fat metabolism in healthy, lean adults.
Evidence suggests A1C levels higher than 7% increase the risks of cardiovascular events in patients 70 years or older with T2D.
Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:
Dalia Elabed, PharmD Candidate 2022, University of South Florida Taneja College of Pharmacy
Kmeone Kingdom, MPH, PharmD Candidate, South College School of Pharmacy
Trina Maglalang RPh, 2022 PharmD Candidate, University of Colorado
Ding Nguyen, PharmD Candidate, University of South Florida Taneja College of Pharmacy
Leyany Feijoo Ramos, PharmD. Candidate, LECOM School of Pharmacy
Destiny Reed, PharmD. Candidate, Florida A&M College of Pharmacy and Pharmaceutical Sciences
Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com